2023-11-07
Join our Team at the Cell Therapy for Autoimmune Disease Summit in Philadelphia on November 28-
30.
PolTREG’s CEO Prof. Piotr Trzonkowski will participate in the discussion panel: “Industry Leader’s
Fireside Chat: The Promises & Challenges of Cell Therapy for Autoimmune Disease”.
PolTREG’s Chief Scientific Officer Dorota Iwaszkiewicz-Grzes will be taking the stage to present a
captivating lecture: “Treating Autoimmunity with Tregs”.
2024-11-14
PolTREG received a new patent from China for anti-gen specific Tregs cellular therapy
2024-09-26
PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases
2024-09-16
China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis
2024-09-09
PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence
2024-07-24
The European Medicines Agency has granted PolTREG preliminary approval to launch a new Phase 2 clinical trial in presymptomatic Type-1 Diabetes.
